About Index Trending news
Analyze
Pricing
Merck

Merck

Merck

Merck's official Twitter handle. Intended for US residents only. Tweeting about our commitment to saving & improving lives.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

Employees

Team size

10000+
Locations
HQ
Headquarters
Adweek

Intel, Under Armour and Merck CEOs Step Down From Trump's Manufacturing Advisory Council

Communities US elections
Xconomy

Invenra Signs On With Merck in Antibody Discovery Partnership

Health Apps & Services
Xconomy

Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails

Health
Xconomy

Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer

Health
Techvibes

TEC Edmonton, Merck Canada Launch Health Tech Incubator

Funding Health Technology
Xconomy

In a Myeloma Setback, Merck Halts Studies Due to Patient Deaths

Health Science
TechMoran

Tunisia, a new frontier for African startups as Merck plan to launch e-health incubation in the country

Funding Technology Global
Xconomy

Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer

Health
TechMoran

Merck Accelerator announces 3 startups to join its program in Nairobi

Health Cloud
Xconomy

Merck Alzheimer Drug Is Latest To Fail In A Big Study

Health Science
TechCrunch , Bloomberg

With billions of dollars at stake, Merck and Palantir partner to discover drugs faster

Health Funding
Xconomy

Vertex Deals Cancer Drugs to Merck for $230M, Staying True to Plan

Health
Xconomy , New York Times Bits

Merck Surges As Bristol’s Immunotherapy Drug Stumbles in Lung Cancer

Health Earnings
Xconomy

Merck, Amgen Invest in Akili as Therapeutic Video Game Moves Ahead

Health Funding
Xconomy

Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact

Health Funding
The Motley Fool

Attention Merck Investors: It's Time to Start Worrying

Xconomy

Gerngross Mulls Buying Back GlycoFi After Merck Closes HQ

The Motley Fool

5 Surprising Comments in Merck's Quarterly Conference Call

The Motley Fool

Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut

The Motley Fool

5 Data Points Wall Street Is Anxiously Awaiting in Merck's Q1 Report

Health Earnings